Actively Recruiting

Phase 4
Age: 76Years +
All Genders
Healthy Volunteers
NCT07502560

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Led by GlaxoSmithKline · Updated on 2026-05-12

33609

Participants Needed

8

Research Sites

574 weeks

Total Duration

On this page

Sponsors

G

GlaxoSmithKline

Lead Sponsor

F

Finnish Vaccine Research;

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

CONDITIONS

Official Title

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Who Can Participate

Age: 76Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Citizens living permanently in Finland who can and will comply with the study requirements
  • Written or witnessed informed consent obtained before any study procedures
  • Age 76 years or older at the time of signing informed consent
Not Eligible

You will not qualify if you...

  • Prior receipt of a Herpes Zoster vaccine
  • History of dementia diagnosis before enrollment, including confirmed cases or ongoing investigations
  • Use of dementia treatment medications prior to enrollment
  • Current or recent cognitive assessments for memory deficits or suspected dementia that are ongoing or inconclusive
  • Severe immunocompromise
  • Participation in another clinical trial involving investigational products or dementia prevention
  • Known severe allergic reactions to vaccine components or similar vaccines
  • Living in a nursing facility

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

GSK Investigational Site

Espoo, Finland, 02230

Actively Recruiting

2

GSK Investigational Site

Helsinki, Finland, 00100

Actively Recruiting

3

GSK Investigational Site

Jarvenpaa, Finland, 04400

Actively Recruiting

4

GSK Investigational Site

Kokkola, Finland, 67100

Actively Recruiting

5

GSK Investigational Site

Oulu, Finland, 90220

Actively Recruiting

6

GSK Investigational Site

Seinäjoki, Finland, 60100

Actively Recruiting

7

GSK Investigational Site

Tampere, Finland, 33100

Actively Recruiting

8

GSK Investigational Site

Turku, Finland, 20520

Actively Recruiting

Loading map...

Research Team

U

US GSK Clinical Trials Call Center

CONTACT

E

EU GSK Clinical Trials Call Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here